GB202214721D0 - A treatment for mental disorders - Google Patents
A treatment for mental disordersInfo
- Publication number
- GB202214721D0 GB202214721D0 GBGB2214721.9A GB202214721A GB202214721D0 GB 202214721 D0 GB202214721 D0 GB 202214721D0 GB 202214721 A GB202214721 A GB 202214721A GB 202214721 D0 GB202214721 D0 GB 202214721D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- mental disorders
- mental
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000020016 psychiatric disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2214721.9A GB202214721D0 (en) | 2022-10-06 | 2022-10-06 | A treatment for mental disorders |
PCT/GB2023/052606 WO2024074850A1 (en) | 2022-10-06 | 2023-10-06 | A treatment for mental disorders |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2214721.9A GB202214721D0 (en) | 2022-10-06 | 2022-10-06 | A treatment for mental disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
GB202214721D0 true GB202214721D0 (en) | 2022-11-23 |
Family
ID=84818032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2214721.9A Ceased GB202214721D0 (en) | 2022-10-06 | 2022-10-06 | A treatment for mental disorders |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB202214721D0 (en) |
WO (1) | WO2024074850A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101489756B (en) | 2006-03-24 | 2013-08-07 | 奥克思利尤姆国际控股公司 | Process for the preparation of a hot-melt extruded laminate |
US9687445B2 (en) | 2012-04-12 | 2017-06-27 | Lts Lohmann Therapie-Systeme Ag | Oral film containing opiate enteric-release beads |
NL2018190B1 (en) * | 2017-01-18 | 2018-07-26 | Procare Beheer B V | Psilocybin or psilocin in combination with cannabinoid |
AU2020259406A1 (en) * | 2019-04-17 | 2021-11-04 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
CN115811975A (en) * | 2020-05-05 | 2023-03-17 | 巴塞尔大学医院 | MDMA treatment to enhance the acute emotional response characteristics of LSD, siloxibin, or other hallucinogens |
WO2023036473A1 (en) * | 2021-09-08 | 2023-03-16 | Cybin Irl Limited | Combination drug therapies |
-
2022
- 2022-10-06 GB GBGB2214721.9A patent/GB202214721D0/en not_active Ceased
-
2023
- 2023-10-06 WO PCT/GB2023/052606 patent/WO2024074850A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024074850A1 (en) | 2024-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL294594A (en) | Methods for treating pemphigus disorders | |
SG10201911828YA (en) | A medical waste treatment device | |
EP4118083A4 (en) | Purine compounds for treating disorders | |
GB202214721D0 (en) | A treatment for mental disorders | |
GB202004161D0 (en) | Filter for a treatment apparatus | |
EP3858286C0 (en) | Tool for a medical treatment | |
EP3858285C0 (en) | Tool for a medical treatment | |
IL307607A (en) | Tetracyclic compounds for treating brain disorders | |
IL288797A (en) | Treatment for synucleinopathies | |
IL280548A (en) | A new medical treatment for pathologic inflammation | |
GB202020549D0 (en) | Treatment for Lysine Degradation-associated Disorders | |
GB202204234D0 (en) | Retinal Disorders | |
GB202204231D0 (en) | Retinal Disorders | |
GB202204230D0 (en) | Retinal Disorders | |
GB202109590D0 (en) | Combination treatment for coronavirus | |
GB202314527D0 (en) | New treatment for pain | |
ZA202207243B (en) | A pharmaceutical combination for the treatment of a cancer | |
GB202007082D0 (en) | Assemblage for forming a treatment chair | |
GB202002038D0 (en) | Compounds for treating bone disorders | |
IL309392A (en) | Retinal disorders | |
IL309393A (en) | Retinal disorders | |
IL311440A (en) | A patient support platform for increasing patient engagement | |
GB202108760D0 (en) | Retinal disorders | |
GB202108756D0 (en) | Retinal disorders | |
GB202108759D0 (en) | Retinal disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |